Bausch + Lomb Corporation
TSX:BLCO.TO · Toronto Stock Exchange
+$0.04 today
Vol 0.00M · Avg 0.00M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-5.6%
avg -1.2%
ROIC
1.5%
avg 1.3%
ROA
-2.6%
avg -0.3%
Analysis
ROIC is currently the strongest return metric at 1.5% versus its period average of 1.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brenton L. Saunders | Chief Executive Officer & Chairman | $7.86M | — | 56 | — | — |
Osama A. Eldessouky | Executive Vice President & Chief Financial Officer | $2.50M | — | 54 | — | — |
A. Robert D. Bailey | Executive Vice President & Chief Legal Officer | $2.05M | — | 63 | — | — |
Yehia Hashad | Executive Vice President of Research & Development and Chief Medical officer | $2.02M | — | 58 | — | — |
Andrew Stewart | President of Global Pharmaceuticals & International Consumer | $1.75M | — | 50 | — | — |
Frederick J. Munsch | Senior Vice President, Controller & Chief Accounting Officer | — | — | 56 | — | — |
Alan Waterhouse CPFA | Executive Vice President and Chief Supply Chain & Operations Officer | — | — | 66 | — | — |
Jonathon L. Kellerman | Chief Compliance Officer | — | — | — | — | — |
Crawford | Chief Communications Officer | — | — | — | — | — |
George Gadkowski | Vice President & Head of Investor Relations & Business Insights | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -63.1% | +70.4% (7yr)10 analysts |
| Revenue | N/A | N/A | -0.1% | +6.7% (7yr)12 analysts |
| Net Income | N/A | N/A | -63.1% | +70.7% (7yr)12 analysts |
| EBIT | N/A | N/A | -27.0% | +4.9% (7yr)12 analysts |
Analysis
Recent growth has been strongest in Revenue at -0.1% over three years. Forward estimates point to Net Income at +70.7% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Curaleaf Holdings, Inc.
TSX:CURA.TO
$3.12B
Trulieve Cannabis Corp.
TRUL.CN
$2.74B
Bausch Health Companies Inc.
TSX:BHC.TO
$2.51B
WELL Health Technologies Corp.
TSX:WELL.TO
$1.12B
Tilray Brands, Inc.
TSX:TLRY.TO
$801.35M
Spectral Medical Inc.
TSX:EDT.TO
$404.92M
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
$366.40M
Zentek Ltd.
ZEN.V
$66.14M
Sona Nanotech Inc.
SONA.CN
$32.60M
Ocumetics Technology Corp.
OTC.V
$30.63M
Who manages BLCO.TO?
Bausch + Lomb Corporation (BLCO.TO) lists 10 active executives. The top listed executive is A. Robert D. Bailey, Executive Vice President & Chief Legal Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.